Researchers analyzed data from 6,035 American adults and reported the following findings:
- MASLD (formerly called non-alcoholic fatty liver disease) was found in 27% of participants, while 16% had signs of liver fibrosis.
- Without excluding comorbidities, both CKD and T2DM independently increased the odds of having MASLD and LF.
- Compared to individuals without these conditions, CKD raised MASLD risk by 27% and LF risk by 82%, while T2DM more than doubled the risk for both outcomes.
- After excluding participants with overlapping conditions, CKD alone was not significantly linked to MASLD, whereas T2DM alone showed a strong association with higher MASLD risk.
- Having both CKD and T2DM did not increase MASLD risk beyond that of diabetes alone, but more than tripled LF risk compared to those without either condition.
- The odds ratio for LF in participants with both CKD and T2DM was 3.50, exceeding the risk with T2DM alone (1.66) or CKD alone (1.38).
- The increased LF risk in patients with both conditions was consistent across demographic and clinical subgroups, suggesting an additive or synergistic effect on liver scarring.
According to the authors, the results carry significant clinical implications. While MASLD is increasingly recognized as a complication of metabolic disorders, liver fibrosis is a more advanced stage of liver damage that can progress to cirrhosis and liver failure. The study’s findings emphasize the importance of routine liver health assessment in people with both diabetes and kidney disease.
Given that transient elastography can detect early fibrosis more reliably than blood-based methods, the researchers advocate for its wider use in at-risk groups. Early detection could enable timely lifestyle interventions, tighter blood sugar and blood pressure control, and possibly drug therapies to slow or prevent progression to advanced liver disease.
"In short, while T2DM alone already places patients at a heightened risk for fatty liver disease, the coexistence of CKD markedly amplifies the danger of significant liver scarring—making vigilant monitoring a medical priority," the authors concluded.
Reference:
Xu, T., & Zhu, W. (2025). Association of chronic kidney disease and type 2 diabetes mellitus with metabolic dysfunction-associated steatotic liver disease and liver fibrosis assessed by transient elastography: A cross-sectional study based on NHANES 2017–2020. Diabetes Research and Clinical Practice, 227, 112418. https://doi.org/10.1016/j.diabres.2025.112418
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.